GLP-1 Therapies Newsletter
Issue #63November 16, 20267 studies

Lift weights on tirzepatide: resistance training preserved 1 kg of muscle in 40 weeks

GLP-1 drugs keep racking up wins — and complications.

This week's research shows they're reshaping treatment for everything from heart disease to osteoarthritis, while raising harder questions about muscle loss, genetic mismatch, and what happens when 1 in 5 users goes off-label.

🏋️ Lift While You Lose: Resistance Training Protects Muscle During Tirzepatide Therapy

  • In a 40-week randomized trial of 120 adults with obesity, adding three weekly resistance exercise sessions to tirzepatide preserved about 1 kg more lean soft tissue mass compared to tirzepatide alone — without changing total weight loss (~22 kg in both groups).
  • The exercise group also gained upper and lower body strength across the board. The tirzepatide-only group lost strength in every measure tested.
  • Fat loss was nearly identical between groups, meaning resistance training carved out a cleaner body composition outcome without touching the scale.

Why it matters: Tirzepatide's weight loss is real, but so is the muscle loss that comes with it. This trial offers a concrete, low-cost adjunct — and reframes the conversation from "how much do you lose" to "what exactly are you losing."

🔗 Nature medicine Journal Article 🗓️ Nov 9

Key Findings

🧬 Wrong Gene, Wrong Drug: Rare Variants Cut Semaglutide Response — But Not Tirzepatide's

  • Among 13,725 GLP-1 drug users in a real-world genomic database, people carrying rare damaging variants in the GLP-1 receptor gene lost significantly less weight on semaglutide than matched non-carriers.
  • Switch to tirzepatide — which hits a second receptor — and those same carriers achieved near-normal weight loss. Rare variants in the second receptor gene didn't blunt tirzepatide's effect either.
💡 Your genes may predict which obesity drug actually works for you.
🥇 Top 1% journal 🔗 Nature metabolism Journal Article 🗓️ Nov 11

💊 1 in 10 U.S. Adults Took a GLP-1 Drug Last Year — and 2 in 5 Modified Their Dose

  • CDC survey data from mid-2025 found roughly 10% of U.S. adults reported GLP-1 use in the past year. About 1 in 5 of those users took a compounded version not reviewed by the FDA for safety or quality.
  • Around 40% of users modified how they took their medication — often citing cost or availability — with the highest rates of modification among younger adults.
💡 Cost and access are quietly reshaping how millions actually take these drugs.
🥇 Top 1% journal 🔗 MMWR. Morbidity and mortality weekly report Journal Article 🗓️ Nov 12

🦴 Triple Agonist Cuts Knee Pain in People With Obesity in Phase 3 Trial

  • Retatrutide — an investigational drug targeting three metabolic receptors simultaneously — was tested in adults with knee osteoarthritis and obesity, published in the New England Journal of Medicine.
  • The trial found meaningful reductions in knee pain, extending the potential use of next-generation incretin drugs well beyond blood sugar and body weight.
💡 The incretin drug frontier now includes joint pain, not just metabolism.
🏆 Top 0.1% journal 🔗 The New England journal of medicine Journal Article 🗓️ Nov 9

🫀 Survodutide Passes Cardiovascular Safety Bar in High-Risk Obesity Trial

  • The SYNCHRONIZE-CVOT phase 3 trial tested survodutide — a dual glucagon and GLP-1 receptor agonist — in adults with obesity and elevated cardiovascular risk, reporting results in The Lancet.
  • The trial established cardiovascular safety for this newer drug class, a required regulatory hurdle that earlier-generation obesity drugs failed to clear.
💡 Another next-gen obesity drug clears the cardiovascular safety threshold.
🥇 Top 1% journal 🔗 Lancet (London, England) Journal Article 🗓️ Nov 9

💉 Blocking Two Muscle-Loss Signals During Semaglutide Therapy Preserved Lean Mass

  • The COURAGE phase 2 trial tested antibodies blocking GDF8 (myostatin) and activin A — two proteins that suppress muscle growth — in people losing weight on semaglutide.
  • The combination approach preserved lean mass during semaglutide-induced weight loss, published in The Lancet, pointing toward a potential pharmacological strategy for the muscle-loss problem.
💡 Pairing a muscle-protecting antibody with semaglutide may offset lean mass loss.
🥇 Top 1% journal 🔗 Lancet (London, England) Journal Article 🗓️ Nov 11

🧠 GLP-1 Drug Didn't Add Benefit for Smoking Cessation on Top of Standard Care

  • In a 71-person neuroimaging sub-trial, 12 weeks of dulaglutide added to varenicline and behavioral counseling produced no significant improvement in abstinence rates, craving, or brain activation compared to placebo.
  • Abstinence was 54% with dulaglutide versus 68% with placebo — not a statistically significant difference, but a result that suggests a ceiling effect when first-line therapy is already strong.
💡 GLP-1 drugs may not add much when the existing treatment is already working well.
🎖️ Top 10% journal 🔗 Brain communications Journal Article 🗓️ Nov 11

Implications

GLP-1 drugs are expanding faster than the evidence can keep up — into joints, muscles, brains, and bariatric aftercare. The clearest unresolved tension: as genetic data shows these drugs work differently depending on who's taking them, the field still lacks prospective tools to match patients to the right drug before the first dose.

Studies in this issue

Primary sources used for this newsletter.

  1. Weekly Retatrutide for Knee Osteoarthritis Pain in Adults with Obesity
    key findingThe New England journal of medicine2026-11-09PMID 43001755
  2. Use and Changes in Glucagon-Like Peptide-1 Medicine Use Among Adults in the United States, 2025
    key findingMMWR. Morbidity and mortality weekly report2026-11-12PMID 43019237
  3. Heart health results with survodutide in adults with obesity and higher heart risk
    key findingLancet (London, England)2026-11-09PMID 43003106
  4. Dulaglutide's effects on brain function and structure during quitting smoking
    key findingBrain communications2026-11-11PMID 43011533